<p>Pathway Capital Management LP 在第三季度購買了 Hims &amp; Hers Health, Inc.（紐約證券交易所代碼：HIMS - 免費報告）的新股份，根據該公司在最近向證券交易委員會（SEC）提交的 13F 文件。該機構投資者購買了 119,279 股公司股票，價值約為 6,766,000 美元。Hims &amp; Hers Health 佔 Pathway Capital Management LP 持有股份的 33.3%，使其成為該公司最大的持倉。根據其最近向證券交易委員會（SEC）提交的文件，Pathway Capital Management LP 擁有 Hims &amp; Hers Health 的 0.05%。</p>
<p>獲取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
<ul>
<li>在 2026 年第一季度之前購買的 5 只高空頭頭寸股票</li>
</ul>
<p>其他幾家對沖基金最近也調整了對 HIMS 的持倉。維吉尼亞退休系統等在第三季度將其在 Hims &amp; Hers Health 的股份提高了 0.8%。維吉尼亞退休系統等現在擁有 25,600 股公司股票，價值 1,452,000 美元，此前在上個季度又購買了 200 股。GAMMA Investing LLC 在第三季度將其在 Hims &amp; Hers Health 的持倉增加了 6.1%。GAMMA Investing LLC 現在擁有 4,098 股公司股票，價值 232,000 美元，此前在此期間又購買了 236 股。Concurrent Investment Advisors LLC 在第三季度將其在 Hims &amp; Hers Health 的持倉增加了 1.8%。Concurrent Investment Advisors LLC 現在擁有 13,984 股公司股票，價值 793,000 美元，此前在此期間又購買了 252 股。Bessemer Group Inc. 在第二季度將其在 Hims &amp; Hers Health 的持倉增加了 105.8%。Bessemer Group Inc. 現在擁有 607 股公司股票，價值 30,000 美元，此前在上個季度又購買了 312 股。最後，True Vision MN LLC 在第二季度將其在 Hims &amp; Hers Health 的股份增加了 3.6%。True Vision MN LLC 現在擁有 9,376 股公司股票，價值 467,000 美元，此前在此期間又購買了 328 股。機構投資者和對沖基金持有公司股票的 63.52%。</p>
<h2>Hims &amp; Hers Health 價格表現</h2>
<p>Hims（紐約證券交易所代碼：HIMS）週二開盤價為 26.45 美元。該公司的債務與股本比率為 1.67，速動比率為 1.64，流動比率為 1.88。該公司的市值為 60.2 億美元，市盈率為 48.97，市盈增長比率為 4.46，貝塔值為 2.37。Hims &amp; Hers Health, Inc. 的一年低點為 23.97 美元，一年高點為 72.98 美元。該股票的 50 日移動平均線為 34.11 美元，200 日移動平均線為 44.09 美元。</p>
<ul>
<li>Hims、Block 和 NRG 剛剛啓動了大規模股票回購</li>
</ul>
<p>Hims &amp; Hers Health（紐約證券交易所代碼：HIMS - 獲取免費報告）最近於 11 月 3 日發佈了其財報。該公司報告本季度每股收益（EPS）為 0.06 美元，低於分析師一致預期的 0.09 美元，差額為 0.03 美元。該公司在本季度的收入為 5.9898 億美元，而分析師預期為 5.7899 億美元。Hims &amp; Hers Health 的淨利潤率為 6.05%，股本回報率為 24.67%。Hims &amp; Hers Health 本季度的收入同比增長 49.2%。在去年同期，該公司每股收益為 0.32 美元。整體來看，股票分析師預計 Hims &amp; Hers Health, Inc. 本財年將發佈 0.29 美元的每股收益。</p>
<p>Hims &amp; Hers Health 宣佈其董事會已於 11 月 17 日批准了一項股票回購計劃，允許公司回購 2.5 億美元的流通股。該回購授權允許公司通過公開市場購買最多 3% 的股票。股票回購計劃通常表明公司的董事會認為其股票被低估。</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>MarketBeat 週報 – 11/17 - 11/21</li>
</ul>
<p>HIMS 最近成為幾份分析師報告的主題。Wall Street Zen 在 11 月 8 日的研究報告中將 Hims &amp; Hers Health 的評級從 “持有” 下調至 “賣出”。Zacks Research 在 1 月 19 日的研究報告中將 Hims &amp; Hers Health 的評級從 “持有” 下調至 “強烈賣出”。美國銀行在 11 月 4 日的研究報告中將 Hims &amp; Hers Health 的目標價從 28.00 美元上調至 32.00 美元，並給予該公司 “表現不佳” 的評級。Evercore ISI 在 1 月 12 日的報告中開始覆蓋 Hims &amp; Hers Health 的股票。他們給予了 “持平” 的評級和 33.00 美元的目標價。最後，巴克萊在 12 月 8 日的報告中開始覆蓋 Hims &amp; Hers Health 的股票。他們對該股票設定了 “增持” 評級和 48.00 美元的目標價。一位投資分析師對該股票給予了強烈買入評級，三位給予了買入評級，九位給予了持有評級，四位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，共識目標價為 42.62 美元。</p>
<p><strong>查看我們關於 HIMS 的最新報告</strong></p>
<h2>Hims &amp; Hers Health 的內部活動</h2>
<p>在 Hims &amp; Hers Health 的其他新聞中，內部人士 Deborah M. Autor 於 12 月 17 日星期三出售了 7,054 股公司股票。股票的平均售價為 36.71 美元，總價值為 258,952.34 美元。交易後，該內部人士持有 6,175 股公司股票，估值約為 226,684.25 美元。這代表其持股減少了 53.32%。該交易已在證券交易委員會的備案中披露，相關信息可通過 SEC 網站獲取。此外，首席運營官 Michael Chi 於 12 月 17 日星期三出售了 13,750 股 Hims &amp; Hers Health 股票。股票的平均售價為 36.71 美元，總交易額為 504,762.50 美元。出售後，首席運營官直接持有 305,161 股公司股票，估值為 11,202,460.31 美元。這筆交易代表其持股減少了 4.31%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去一個季度中，內部人士已出售 131,974 股公司股票，價值 4,763,800 美元。公司內部人士持有公司股票的 13.71%。</p>
<h2>Hims &amp; Hers Health 概況</h2>
<p>(免費報告)</p>
<p>Hims &amp; Hers Health, Inc 是一個遠程醫療平台，提供直接面向消費者的個人護理產品和虛擬醫療服務，服務於美國市場。該公司以 Hims &amp; Hers 品牌運營，提供一個綜合數字體驗，將用户與持牌醫療提供者連接，使其能夠進行在線諮詢和開處方，涵蓋多種健康問題。其遠程醫療基礎設施支持處方藥和非處方產品，並提供送貨上門服務。</p>
<p>公司的產品組合涵蓋男性和女性健康的關鍵領域，包括脱髮治療、性健康療法、護膚方案和心理健康支持。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Hims &amp; Hers Health</li>
<li>黃金市場崩潰的那一天</li>
<li>忘掉人工智能，這將是下一個重大科技突破</li>
<li>~15,000 億美元的 SpaceX IPO：首次公開募股機會</li>
<li>黃金正在變得稀缺。</li>
<li>警報：在明天市場開盤前拋售這五隻股票！</li>
</ul>
<p><strong>想看看其他對 HIMS 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Hims &amp; Hers Health, Inc. (NYSE:HIMS - 免費報告) 的最新 13F 備案和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
<p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Hims &amp; Hers Health 並不在名單上。</p>
<p>雖然 Hims &amp; Hers Health 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

標普醫療保健服務 ETF - SPDR

醫療業 ETF - SPDR

2 倍做多 HIMS ETF - Defiance

醫療業 ETF - Vanguard

美國醫療保健供應商 ETF - iShares

HIMS

HIMY

標普全球醫療股指數 ETF - iShares

<p>Pathway Capital Management LP 收購了 119,279 股 Hims & Hers Health, Inc.（NYSE:HIMS），價值約為 677 萬美元，使其成為其投資組合中最大的持倉。其他機構投資者也增加了對 Hims & Hers Health 的持股。該公司報告了上個季度的收入為 5.9898 億美元，未能達到每股收益預期，但顯示出同比 49.2% 的收入增長。Hims & Hers Health 的董事會批准了一項 2.5 億美元的股票回購計劃，表明對股票價值的信心</p>

<p>Pathway Capital Management LP bought a new position in shares of Hims &amp; Hers Health, Inc. (NYSE:HIMS - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 119,279 shares of the company's stock, valued at approximately $6,766,000. Hims &amp; Hers Health accounts for 33.3% of Pathway Capital Management LP's holdings, making the stock its largest position. Pathway Capital Management LP owned 0.05% of Hims &amp; Hers Health as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Pathway Capital Management LP 在第三季度購買了 Hims &amp; Hers Health, Inc.（紐約證券交易所代碼：HIMS - 免費報告）的新股份，根據該公司在最近向證券交易委員會（SEC）提交的 13F 文件。該機構投資者購買了 119,279 股公司股票，價值約為 6,766,000 美元。Hims &amp; Hers Health 佔 Pathway Capital Management LP 持有股份的 33.3%，使其成為該公司最大的持倉。根據其最近向證券交易委員會（SEC）提交的文件，Pathway Capital Management LP 擁有 Hims &amp; Hers Health 的 0.05%。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
</div><ul>
<li>5 High Short-Interest Stocks to Buy Before Q1 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>在 2026 年第一季度之前購買的 5 只高空頭頭寸股票</li>
</ul>
</div><p>Several other hedge funds have also recently modified their holdings of HIMS. VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in shares of Hims &amp; Hers Health by 0.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company's stock valued at $1,452,000 after buying an additional 200 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Hims &amp; Hers Health by 6.1% in the third quarter. GAMMA Investing LLC now owns 4,098 shares of the company's stock valued at $232,000 after purchasing an additional 236 shares during the period. Concurrent Investment Advisors LLC grew its holdings in shares of Hims &amp; Hers Health by 1.8% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company's stock worth $793,000 after purchasing an additional 252 shares during the period. Bessemer Group Inc. increased its holdings in Hims &amp; Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after purchasing an additional 312 shares during the last quarter. Finally, True Vision MN LLC increased its stake in Hims &amp; Hers Health by 3.6% during the second quarter. True Vision MN LLC now owns 9,376 shares of the company's stock worth $467,000 after purchasing an additional 328 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金最近也調整了對 HIMS 的持倉。維吉尼亞退休系統等在第三季度將其在 Hims &amp; Hers Health 的股份提高了 0.8%。維吉尼亞退休系統等現在擁有 25,600 股公司股票，價值 1,452,000 美元，此前在上個季度又購買了 200 股。GAMMA Investing LLC 在第三季度將其在 Hims &amp; Hers Health 的持倉增加了 6.1%。GAMMA Investing LLC 現在擁有 4,098 股公司股票，價值 232,000 美元，此前在此期間又購買了 236 股。Concurrent Investment Advisors LLC 在第三季度將其在 Hims &amp; Hers Health 的持倉增加了 1.8%。Concurrent Investment Advisors LLC 現在擁有 13,984 股公司股票，價值 793,000 美元，此前在此期間又購買了 252 股。Bessemer Group Inc. 在第二季度將其在 Hims &amp; Hers Health 的持倉增加了 105.8%。Bessemer Group Inc. 現在擁有 607 股公司股票，價值 30,000 美元，此前在上個季度又購買了 312 股。最後，True Vision MN LLC 在第二季度將其在 Hims &amp; Hers Health 的股份增加了 3.6%。True Vision MN LLC 現在擁有 9,376 股公司股票，價值 467,000 美元，此前在此期間又購買了 328 股。機構投資者和對沖基金持有公司股票的 63.52%。</p>
</div><h2>Hims &amp; Hers Health Price Performance</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 價格表現</h2>
</div><p>Shares of NYSE:HIMS opened at $26.45 on Tuesday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The company has a market capitalization of $6.02 billion, a PE ratio of 48.97, a price-to-earnings-growth ratio of 4.46 and a beta of 2.37. Hims &amp; Hers Health, Inc. has a one year low of $23.97 and a one year high of $72.98. The stock has a fifty day moving average of $34.11 and a 200-day moving average of $44.09.</p>
<div class="lb-trans"><p>Hims（紐約證券交易所代碼：HIMS）週二開盤價為 26.45 美元。該公司的債務與股本比率為 1.67，速動比率為 1.64，流動比率為 1.88。該公司的市值為 60.2 億美元，市盈率為 48.97，市盈增長比率為 4.46，貝塔值為 2.37。Hims &amp; Hers Health, Inc. 的一年低點為 23.97 美元，一年高點為 72.98 美元。該股票的 50 日移動平均線為 34.11 美元，200 日移動平均線為 44.09 美元。</p>
</div><ul>
<li>Hims, Block, and NRG Just Launched Huge Stock Buybacks</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims、Block 和 NRG 剛剛啓動了大規模股票回購</li>
</ul>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.03). The business had revenue of $598.98 million during the quarter, compared to analysts' expectations of $578.99 million. Hims &amp; Hers Health had a net margin of 6.05% and a return on equity of 24.67%. Hims &amp; Hers Health's revenue for the quarter was up 49.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.32 EPS. As a group, equities analysts anticipate that Hims &amp; Hers Health, Inc. will post 0.29 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health（紐約證券交易所代碼：HIMS - 獲取免費報告）最近於 11 月 3 日發佈了其財報。該公司報告本季度每股收益（EPS）為 0.06 美元，低於分析師一致預期的 0.09 美元，差額為 0.03 美元。該公司在本季度的收入為 5.9898 億美元，而分析師預期為 5.7899 億美元。Hims &amp; Hers Health 的淨利潤率為 6.05%，股本回報率為 24.67%。Hims &amp; Hers Health 本季度的收入同比增長 49.2%。在去年同期，該公司每股收益為 0.32 美元。整體來看，股票分析師預計 Hims &amp; Hers Health, Inc. 本財年將發佈 0.29 美元的每股收益。</p>
</div><p>Hims &amp; Hers Health declared that its board has approved a share repurchase program on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 3% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its stock is undervalued.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health 宣佈其董事會已於 11 月 17 日批准了一項股票回購計劃，允許公司回購 2.5 億美元的流通股。該回購授權允許公司通過公開市場購買最多 3% 的股票。股票回購計劃通常表明公司的董事會認為其股票被低估。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>MarketBeat Week in Review – 11/17 - 11/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 11/17 - 11/21</li>
</ul>
</div><p>HIMS has been the subject of several recent analyst reports. Wall Street Zen cut Hims &amp; Hers Health from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 8th. Zacks Research downgraded shares of Hims &amp; Hers Health from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Monday, January 19th. Bank of America increased their price objective on Hims &amp; Hers Health from $28.00 to $32.00 and gave the company an &#34;underperform&#34; rating in a research note on Tuesday, November 4th. Evercore ISI started coverage on shares of Hims &amp; Hers Health in a report on Monday, January 12th. They issued an &#34;in-line&#34; rating and a $33.00 target price for the company. Finally, Barclays initiated coverage on shares of Hims &amp; Hers Health in a report on Monday, December 8th. They set an &#34;overweight&#34; rating and a $48.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $42.62.</p>
<div class="lb-trans"><p>HIMS 最近成為幾份分析師報告的主題。Wall Street Zen 在 11 月 8 日的研究報告中將 Hims &amp; Hers Health 的評級從 “持有” 下調至 “賣出”。Zacks Research 在 1 月 19 日的研究報告中將 Hims &amp; Hers Health 的評級從 “持有” 下調至 “強烈賣出”。美國銀行在 11 月 4 日的研究報告中將 Hims &amp; Hers Health 的目標價從 28.00 美元上調至 32.00 美元，並給予該公司 “表現不佳” 的評級。Evercore ISI 在 1 月 12 日的報告中開始覆蓋 Hims &amp; Hers Health 的股票。他們給予了 “持平” 的評級和 33.00 美元的目標價。最後，巴克萊在 12 月 8 日的報告中開始覆蓋 Hims &amp; Hers Health 的股票。他們對該股票設定了 “增持” 評級和 48.00 美元的目標價。一位投資分析師對該股票給予了強烈買入評級，三位給予了買入評級，九位給予了持有評級，四位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，共識目標價為 42.62 美元。</p>
</div><p><strong>View Our Latest Report on HIMS</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 HIMS 的最新報告</strong></p>
</div><h2>Insider Activity at Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 的內部活動</h2>
</div><p>In other Hims &amp; Hers Health news, insider Deborah M. Autor sold 7,054 shares of the company's stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the transaction, the insider owned 6,175 shares in the company, valued at approximately $226,684.25. This represents a 53.32% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, COO Michael Chi sold 13,750 shares of Hims &amp; Hers Health stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the sale, the chief operating officer directly owned 305,161 shares of the company's stock, valued at $11,202,460.31. This trade represents a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 131,974 shares of company stock worth $4,763,800. Company insiders own 13.71% of the company's stock.</p>
<div class="lb-trans"><p>在 Hims &amp; Hers Health 的其他新聞中，內部人士 Deborah M. Autor 於 12 月 17 日星期三出售了 7,054 股公司股票。股票的平均售價為 36.71 美元，總價值為 258,952.34 美元。交易後，該內部人士持有 6,175 股公司股票，估值約為 226,684.25 美元。這代表其持股減少了 53.32%。該交易已在證券交易委員會的備案中披露，相關信息可通過 SEC 網站獲取。此外，首席運營官 Michael Chi 於 12 月 17 日星期三出售了 13,750 股 Hims &amp; Hers Health 股票。股票的平均售價為 36.71 美元，總交易額為 504,762.50 美元。出售後，首席運營官直接持有 305,161 股公司股票，估值為 11,202,460.31 美元。這筆交易代表其持股減少了 4.31%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去一個季度中，內部人士已出售 131,974 股公司股票，價值 4,763,800 美元。公司內部人士持有公司股票的 13.71%。</p>
</div><h2>Hims &amp; Hers Health Profile</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 概況</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Hims &amp; Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims &amp; Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc 是一個遠程醫療平台，提供直接面向消費者的個人護理產品和虛擬醫療服務，服務於美國市場。該公司以 Hims &amp; Hers 品牌運營，提供一個綜合數字體驗，將用户與持牌醫療提供者連接，使其能夠進行在線諮詢和開處方，涵蓋多種健康問題。其遠程醫療基礎設施支持處方藥和非處方產品，並提供送貨上門服務。</p>
</div><p>The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.</p>
<div class="lb-trans"><p>公司的產品組合涵蓋男性和女性健康的關鍵領域，包括脱髮治療、性健康療法、護膚方案和心理健康支持。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>The day the gold market broke</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>Gold’s getting scarce.</li>
<li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Hims &amp; Hers Health</li>
<li>黃金市場崩潰的那一天</li>
<li>忘掉人工智能，這將是下一個重大科技突破</li>
<li>~15,000 億美元的 SpaceX IPO：首次公開募股機會</li>
<li>黃金正在變得稀缺。</li>
<li>警報：在明天市場開盤前拋售這五隻股票！</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding HIMS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims &amp; Hers Health, Inc. (NYSE:HIMS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 HIMS 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Hims &amp; Hers Health, Inc. (NYSE:HIMS - 免費報告) 的最新 13F 備案和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Hims &amp; Hers Health 並不在名單上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Hims &amp; Hers Health 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

119,279 Shares in Hims & Hers Health, Inc. $HIMS Purchased by Pathway Capital Management LP

Market Beat

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

Pathway Capital Management LP 購入了 119,279 股 Hims & Hers Health, Inc.的股票，股票代碼為$HIMS